3 Reason Why This Analyst Says CRISPR Therapeutics Is A Biotech Winner
CRISPR Therapeutics AG (NASDAQ: CRSP) has a diversified pipeline with potential CTX001 commercialization and CTX110 potential approval expected in 2024, according to BMO Capital Markets.